{"id":14777,"date":"2024-11-25T00:00:00","date_gmt":"2024-11-25T04:00:00","guid":{"rendered":"https:\/\/livingstagenew.wpenginepowered.com\/transaction\/niterra-ventures-company-invests-18m-additional-funding-in-neoplas-med-gmbh\/"},"modified":"2026-06-25T09:38:21","modified_gmt":"2026-06-25T13:38:21","slug":"niterra-ventures-company-invests-18m-additional-funding-in-neoplas-med-gmbh","status":"publish","type":"transaction","link":"https:\/\/livingstonepartners.com\/es\/transaction\/niterra-ventures-company-invests-18m-additional-funding-in-neoplas-med-gmbh\/","title":{"rendered":"La empresa Niterra Ventures invierte 18 millones de d\u00f3lares adicionales en neoplas med GmbH"},"content":{"rendered":"\n<p><strong>El equipo de Healthcare de Livingstone en D\u00fcsseldorf ha seguido asesorando a <\/strong><a target=\"_blank\" rel=\"noopener noreferrer\" href=\"https:\/\/neoplas-med.eu\/en\/\"><strong>neoplas med GmbH<\/strong><\/a><strong> en su tercera ronda de financiaci\u00f3n. La empresa pionera en tecnolog\u00eda m\u00e9dica con sede en Greifswald intensifica su colaboraci\u00f3n estrat\u00e9gica con <\/strong><a target=\"_blank\" rel=\"noopener noreferrer\" href=\"https:\/\/niterraventures.com\/\"><strong>Niterra Ventures Company<\/strong><\/a><strong> a trav\u00e9s de una ampliaci\u00f3n de capital de 18M$ para seguir ampliando el mercado de sus innovadores productos tecnol\u00f3gicos para el cuidado de heridas. Con una inversi\u00f3n total de 25M$, Niterra Ventures Company invirti\u00f3 previamente en neoplas med en 2022 y 2023.<\/strong><\/p><p>neoplas med, una empresa derivada del Instituto Leibniz de Ciencia y Tecnolog\u00eda del Plasma e.V. (INP), ha creado el chorro de plasma fr\u00edo de arg\u00f3n, kINPen\u00ae MED, un innovador \u00abbol\u00edgrafo de plasma\u00bb que dirige un chorro de plasma preciso sobre las heridas y acelera notablemente su cicatrizaci\u00f3n. Los estudios cl\u00ednicos demuestran que el tiempo de tratamiento puede reducirse en un 50% en comparaci\u00f3n con los m\u00e9todos convencionales, sin efectos secundarios ni desarrollo de resistencias. neoplas med es casi la \u00fanica empresa que utiliza el gas inerte arg\u00f3n para esta terapia casi indolora y r\u00e1pida, que trata tanto heridas infectadas como cr\u00f3nicas. Con su \u00ab bol\u00edgrafo de plasma \u00bb, neoplas med es el \u00fanico fabricante de productos de plasma fr\u00edo en Europa que cuenta con la certificaci\u00f3n del Reglamento Europeo de Productos Sanitarios (MDR).<\/p><p><em>\u00abLa inversi\u00f3n adicional de Niterra Ventures Company nos abre oportunidades completamente nuevas para acceder a m\u00e1s mercados, ampliar nuestra plataforma tecnol\u00f3gica y desarrollar nuevos productos\u00bb<\/em>, ha declarado <strong>Ulrike Sailer, CEO de neoplas med<\/strong>.<em> \u00abNo solo estamos dando un gran paso adelante, sino tambi\u00e9n asegurando y creando nuevos puestos de trabajo en el sector de la alta tecnolog\u00eda\u00bb.<\/em><\/p><p>En Alemania, el 75% de las cl\u00ednicas universitarias y numerosas consultas m\u00e9dicas y hospitales utilizan la terapia de plasma fr\u00edo Argon Jet patentada por neoplas med, que se ha aplicado en m\u00e1s de 500.000 tratamientos en todo el mundo, incluidas las principales cl\u00ednicas de Oriente Medio. Esta financiaci\u00f3n se utilizar\u00e1 para seguir desarrollando su plataforma tecnol\u00f3gica y ampliar sus operaciones a escala internacional, centr\u00e1ndose principalmente en Estados Unidos, Europa y Oriente Medio.<\/p><p><em>\u00abNiterra Ventures Company est\u00e1 estableciendo nuevas oportunidades de negocio en los sectores m\u00e9dico, cleantech, energ\u00eda e IoT para mejorar la calidad de vida utilizando tecnolog\u00edas de vanguardia\u00bb<\/em>, dijo <strong>Dirk Schapeler, Presidente de Niterra Ventures Company.<\/strong> <em>\u00abHemos estado trabajando estrechamente con neoplas med en los \u00faltimos a\u00f1os y estamos entusiasmados de ver el impacto del plasma fr\u00edo de arg\u00f3n kINPen en los pacientes. Por lo tanto, nuestra inversi\u00f3n de seguimiento era un paso l\u00f3gico\u00bb.<\/em><\/p><p>Como parte de su esfuerzo en el campo de la medicina, la empresa Niterra Ventures est\u00e1 invirtiendo en tecnolog\u00eda para detectar y evaluar afecciones cardiol\u00f3gicas, oncol\u00f3gicas, neurol\u00f3gicas y de hipertensi\u00f3n.<\/p><p><em>\u00abEstamos orgullosos de apoyar a neoplas med en su ambiciosa trayectoria de crecimiento, facilitando la consecuci\u00f3n de nuevos hitos y el \u00e9xito continuado. La tecnolog\u00eda de plasma fr\u00edo de neoplas med representa un avance sustancial en el sector Healthcare, aportando soluciones innovadoras que mejoran la eficacia de los tratamientos y la atenci\u00f3n a los pacientes en m\u00faltiples disciplinas m\u00e9dicas\u00bb<\/em>, dijo el<a rel=\"noopener noreferrer\" href=\"https:\/\/livingstonepartners.com\/es\/team\/dr-ralf-nowak\/\"> Dr. Ralf Nowak, Socio de Livingstone.<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Livingstone act\u00faa como asesor financiero exclusivo de neoplas med GmbH, tras las exitosas rondas de 2022 y 2023<\/p>\n","protected":false},"featured_media":2275,"template":"","meta":{"_acf_changed":false,"footnotes":"","_links_to":"","_links_to_target":""},"client-type":[],"region":[],"sector":[],"service":[],"transaction-type":[],"class_list":["post-14777","transaction","type-transaction","status-publish","has-post-thumbnail","hentry"],"acf":{"team_members":[1773,1756],"date":"20241125","client_type":46,"type":[1023],"region":[402,396],"services":[464],"sectors":[843,852],"related_transactions":"","related_testimonials":[53139,53140,53141],"contacts":[1347,1267]},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>La empresa Niterra Ventures invierte 18 millones de d\u00f3lares adicionales en neoplas med GmbH - Livingstone Partners<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/livingstonepartners.com\/es\/transaction\/niterra-ventures-company-invests-18m-additional-funding-in-neoplas-med-gmbh\/\" \/>\n<meta property=\"og:locale\" content=\"es_ES\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"La empresa Niterra Ventures invierte 18 millones de d\u00f3lares adicionales en neoplas med GmbH - Livingstone Partners\" \/>\n<meta property=\"og:description\" content=\"Livingstone act\u00faa como asesor financiero exclusivo de neoplas med GmbH, tras las exitosas rondas de 2022 y 2023\" \/>\n<meta property=\"og:url\" content=\"https:\/\/livingstonepartners.com\/es\/transaction\/niterra-ventures-company-invests-18m-additional-funding-in-neoplas-med-gmbh\/\" \/>\n<meta property=\"og:site_name\" content=\"Livingstone Partners\" \/>\n<meta property=\"article:modified_time\" content=\"2026-06-25T13:38:21+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/livingstonepartners.com\/wp-content\/uploads\/2026\/05\/65c7c708.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"800\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Tiempo de lectura\" \/>\n\t<meta name=\"twitter:data1\" content=\"3 minutos\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/livingstonepartners.com\\\/es\\\/transaction\\\/niterra-ventures-company-invests-18m-additional-funding-in-neoplas-med-gmbh\\\/\",\"url\":\"https:\\\/\\\/livingstonepartners.com\\\/es\\\/transaction\\\/niterra-ventures-company-invests-18m-additional-funding-in-neoplas-med-gmbh\\\/\",\"name\":\"La empresa Niterra Ventures invierte 18 millones de d\u00f3lares adicionales en neoplas med GmbH - Livingstone Partners\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/livingstonepartners.com\\\/es\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/livingstonepartners.com\\\/es\\\/transaction\\\/niterra-ventures-company-invests-18m-additional-funding-in-neoplas-med-gmbh\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/livingstonepartners.com\\\/es\\\/transaction\\\/niterra-ventures-company-invests-18m-additional-funding-in-neoplas-med-gmbh\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/livingstonepartners.com\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/65c7c708.png\",\"datePublished\":\"2024-11-25T04:00:00+00:00\",\"dateModified\":\"2026-06-25T13:38:21+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/livingstonepartners.com\\\/es\\\/transaction\\\/niterra-ventures-company-invests-18m-additional-funding-in-neoplas-med-gmbh\\\/#breadcrumb\"},\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/livingstonepartners.com\\\/es\\\/transaction\\\/niterra-ventures-company-invests-18m-additional-funding-in-neoplas-med-gmbh\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/livingstonepartners.com\\\/es\\\/transaction\\\/niterra-ventures-company-invests-18m-additional-funding-in-neoplas-med-gmbh\\\/#primaryimage\",\"url\":\"https:\\\/\\\/livingstonepartners.com\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/65c7c708.png\",\"contentUrl\":\"https:\\\/\\\/livingstonepartners.com\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/65c7c708.png\",\"width\":1200,\"height\":800},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/livingstonepartners.com\\\/es\\\/transaction\\\/niterra-ventures-company-invests-18m-additional-funding-in-neoplas-med-gmbh\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Homepage\",\"item\":\"https:\\\/\\\/livingstonepartners.com\\\/es\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Transactions\",\"item\":\"https:\\\/\\\/livingstonepartners.com\\\/es\\\/transaction\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"La empresa Niterra Ventures invierte 18 millones de d\u00f3lares adicionales en neoplas med GmbH\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/livingstonepartners.com\\\/es\\\/#website\",\"url\":\"https:\\\/\\\/livingstonepartners.com\\\/es\\\/\",\"name\":\"Livingstone Partners\",\"description\":\"Deals Done Right.\",\"publisher\":{\"@id\":\"https:\\\/\\\/livingstonepartners.com\\\/es\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/livingstonepartners.com\\\/es\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"es\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/livingstonepartners.com\\\/es\\\/#organization\",\"name\":\"Livingstone Partners\",\"url\":\"https:\\\/\\\/livingstonepartners.com\\\/es\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/livingstonepartners.com\\\/es\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/livingstonepartners.com\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/logo_livingstone.svg\",\"contentUrl\":\"https:\\\/\\\/livingstonepartners.com\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/logo_livingstone.svg\",\"caption\":\"Livingstone Partners\"},\"image\":{\"@id\":\"https:\\\/\\\/livingstonepartners.com\\\/es\\\/#\\\/schema\\\/logo\\\/image\\\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"La empresa Niterra Ventures invierte 18 millones de d\u00f3lares adicionales en neoplas med GmbH - Livingstone Partners","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/livingstonepartners.com\/es\/transaction\/niterra-ventures-company-invests-18m-additional-funding-in-neoplas-med-gmbh\/","og_locale":"es_ES","og_type":"article","og_title":"La empresa Niterra Ventures invierte 18 millones de d\u00f3lares adicionales en neoplas med GmbH - Livingstone Partners","og_description":"Livingstone act\u00faa como asesor financiero exclusivo de neoplas med GmbH, tras las exitosas rondas de 2022 y 2023","og_url":"https:\/\/livingstonepartners.com\/es\/transaction\/niterra-ventures-company-invests-18m-additional-funding-in-neoplas-med-gmbh\/","og_site_name":"Livingstone Partners","article_modified_time":"2026-06-25T13:38:21+00:00","og_image":[{"width":1200,"height":800,"url":"https:\/\/livingstonepartners.com\/wp-content\/uploads\/2026\/05\/65c7c708.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_misc":{"Tiempo de lectura":"3 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/livingstonepartners.com\/es\/transaction\/niterra-ventures-company-invests-18m-additional-funding-in-neoplas-med-gmbh\/","url":"https:\/\/livingstonepartners.com\/es\/transaction\/niterra-ventures-company-invests-18m-additional-funding-in-neoplas-med-gmbh\/","name":"La empresa Niterra Ventures invierte 18 millones de d\u00f3lares adicionales en neoplas med GmbH - Livingstone Partners","isPartOf":{"@id":"https:\/\/livingstonepartners.com\/es\/#website"},"primaryImageOfPage":{"@id":"https:\/\/livingstonepartners.com\/es\/transaction\/niterra-ventures-company-invests-18m-additional-funding-in-neoplas-med-gmbh\/#primaryimage"},"image":{"@id":"https:\/\/livingstonepartners.com\/es\/transaction\/niterra-ventures-company-invests-18m-additional-funding-in-neoplas-med-gmbh\/#primaryimage"},"thumbnailUrl":"https:\/\/livingstonepartners.com\/wp-content\/uploads\/2026\/05\/65c7c708.png","datePublished":"2024-11-25T04:00:00+00:00","dateModified":"2026-06-25T13:38:21+00:00","breadcrumb":{"@id":"https:\/\/livingstonepartners.com\/es\/transaction\/niterra-ventures-company-invests-18m-additional-funding-in-neoplas-med-gmbh\/#breadcrumb"},"inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/livingstonepartners.com\/es\/transaction\/niterra-ventures-company-invests-18m-additional-funding-in-neoplas-med-gmbh\/"]}]},{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/livingstonepartners.com\/es\/transaction\/niterra-ventures-company-invests-18m-additional-funding-in-neoplas-med-gmbh\/#primaryimage","url":"https:\/\/livingstonepartners.com\/wp-content\/uploads\/2026\/05\/65c7c708.png","contentUrl":"https:\/\/livingstonepartners.com\/wp-content\/uploads\/2026\/05\/65c7c708.png","width":1200,"height":800},{"@type":"BreadcrumbList","@id":"https:\/\/livingstonepartners.com\/es\/transaction\/niterra-ventures-company-invests-18m-additional-funding-in-neoplas-med-gmbh\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Homepage","item":"https:\/\/livingstonepartners.com\/es\/"},{"@type":"ListItem","position":2,"name":"Transactions","item":"https:\/\/livingstonepartners.com\/es\/transaction\/"},{"@type":"ListItem","position":3,"name":"La empresa Niterra Ventures invierte 18 millones de d\u00f3lares adicionales en neoplas med GmbH"}]},{"@type":"WebSite","@id":"https:\/\/livingstonepartners.com\/es\/#website","url":"https:\/\/livingstonepartners.com\/es\/","name":"Livingstone Partners","description":"Deals Done Right.","publisher":{"@id":"https:\/\/livingstonepartners.com\/es\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/livingstonepartners.com\/es\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"es"},{"@type":"Organization","@id":"https:\/\/livingstonepartners.com\/es\/#organization","name":"Livingstone Partners","url":"https:\/\/livingstonepartners.com\/es\/","logo":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/livingstonepartners.com\/es\/#\/schema\/logo\/image\/","url":"https:\/\/livingstonepartners.com\/wp-content\/uploads\/2026\/05\/logo_livingstone.svg","contentUrl":"https:\/\/livingstonepartners.com\/wp-content\/uploads\/2026\/05\/logo_livingstone.svg","caption":"Livingstone Partners"},"image":{"@id":"https:\/\/livingstonepartners.com\/es\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/livingstonepartners.com\/es\/wp-json\/wp\/v2\/transaction\/14777","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/livingstonepartners.com\/es\/wp-json\/wp\/v2\/transaction"}],"about":[{"href":"https:\/\/livingstonepartners.com\/es\/wp-json\/wp\/v2\/types\/transaction"}],"version-history":[{"count":1,"href":"https:\/\/livingstonepartners.com\/es\/wp-json\/wp\/v2\/transaction\/14777\/revisions"}],"predecessor-version":[{"id":66481,"href":"https:\/\/livingstonepartners.com\/es\/wp-json\/wp\/v2\/transaction\/14777\/revisions\/66481"}],"acf:post":[{"embeddable":true,"href":"https:\/\/livingstonepartners.com\/es\/wp-json\/wp\/v2\/team-member\/1267"},{"embeddable":true,"href":"https:\/\/livingstonepartners.com\/es\/wp-json\/wp\/v2\/team-member\/1347"},{"embeddable":true,"href":"https:\/\/livingstonepartners.com\/es\/wp-json\/wp\/v2\/testimonial\/53141"},{"embeddable":true,"href":"https:\/\/livingstonepartners.com\/es\/wp-json\/wp\/v2\/testimonial\/53140"},{"embeddable":true,"href":"https:\/\/livingstonepartners.com\/es\/wp-json\/wp\/v2\/testimonial\/53139"},{"embeddable":true,"href":"https:\/\/livingstonepartners.com\/es\/wp-json\/wp\/v2\/team-member\/1756"},{"embeddable":true,"href":"https:\/\/livingstonepartners.com\/es\/wp-json\/wp\/v2\/team-member\/1773"}],"acf:term":[{"embeddable":true,"taxonomy":"sector","href":"https:\/\/livingstonepartners.com\/es\/wp-json\/wp\/v2\/sector\/852"},{"embeddable":true,"taxonomy":"sector","href":"https:\/\/livingstonepartners.com\/es\/wp-json\/wp\/v2\/sector\/843"},{"embeddable":true,"taxonomy":"service","href":"https:\/\/livingstonepartners.com\/es\/wp-json\/wp\/v2\/service\/464"},{"embeddable":true,"taxonomy":"region","href":"https:\/\/livingstonepartners.com\/es\/wp-json\/wp\/v2\/region\/396"},{"embeddable":true,"taxonomy":"region","href":"https:\/\/livingstonepartners.com\/es\/wp-json\/wp\/v2\/region\/402"},{"embeddable":true,"taxonomy":"transaction-type","href":"https:\/\/livingstonepartners.com\/es\/wp-json\/wp\/v2\/transaction-type\/1023"},{"embeddable":true,"taxonomy":"client-type","href":"https:\/\/livingstonepartners.com\/es\/wp-json\/wp\/v2\/client-type\/46"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/livingstonepartners.com\/es\/wp-json\/wp\/v2\/media\/2275"}],"wp:attachment":[{"href":"https:\/\/livingstonepartners.com\/es\/wp-json\/wp\/v2\/media?parent=14777"}],"wp:term":[{"taxonomy":"client-type","embeddable":true,"href":"https:\/\/livingstonepartners.com\/es\/wp-json\/wp\/v2\/client-type?post=14777"},{"taxonomy":"region","embeddable":true,"href":"https:\/\/livingstonepartners.com\/es\/wp-json\/wp\/v2\/region?post=14777"},{"taxonomy":"sector","embeddable":true,"href":"https:\/\/livingstonepartners.com\/es\/wp-json\/wp\/v2\/sector?post=14777"},{"taxonomy":"service","embeddable":true,"href":"https:\/\/livingstonepartners.com\/es\/wp-json\/wp\/v2\/service?post=14777"},{"taxonomy":"transaction-type","embeddable":true,"href":"https:\/\/livingstonepartners.com\/es\/wp-json\/wp\/v2\/transaction-type?post=14777"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}